Here are the files for the UCSF Phase II high-dose ¹³¹I-MIBG protocol for treatment of patients having malignant pheochromocytomas or paragangliomas

MIBG Protocol PDF

MIBG Protocol Stem Cell Harvest PDF

MIBG Protocol Consent Form PDF

In order for ¹³¹I-MIBG therapy to achieve a remission for patients with malignant pheochromocytoma, sufficient doses of ¹³¹I-MIBG must enter tumor cells. In the past, high-dose ¹³¹I-MIBG therapy has not been possible, due to the dangers of myelosuppression and the logistical difficulties and unreliability of bone marrow harvest and transplant. The development of peripheral blood stem cell leukophoresis and cryopreservation has made it possible to treat other malignancies more aggressively and more successfully. Similarly, it is now possible to treat patients with malignant pheochromocytoma more aggressively with ¹³¹I-MIBG, since peripheral blood stem cells may be collected in advance such that they may be reinfused in the event of prolonged myelosuppression following high-dose ¹³¹I-MIBG therapy.